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Background:  Adrenergic activation is a key determinant of heart failure (HF) outcomes. The Alpha-2C adrenergic receptor (A2C-AR) Del 
322-325 polymorphism is a loss of function variant. We examined the interaction between A2C-AR Del 322-325 and beta-blocker (BB) dose 
with cardiovascular (CV) outcomes in the HF-ACTION DNA substudy.
methods:  HF-ACTION was a randomized, multicenter trial enrolling 2331 ambulatory HF patients (NYHA class II-IV, left ventricular 
ejection fraction<0.35) randomized to exercise training vs. usual care, with median follow up of 2.5 years. A subset of patients provided 
plasma for genotyping A2C-AR as wild type or Del carriers (≥1 Del 322-325 allele). Interaction between A2C-AR polymorphism and BB 
doses (high vs. low dose, defined as > or ≤25mg daily carvedilol equivalents) with CV outcomes was tested using Cox proportional hazards 
regression and by race.
results:  Genotype data was available for 965 patients (94% on BB). Del carrier prevalence was 28.3% (60% in blacks, 12.7% in whites). 
Table 1 displays gene-dose interaction with outcomes.
conclusion:  Although no interaction between A2C-AR genotype and BB dose was found in the overall population, BB dose appeared to 
influence outcomes when the analysis was stratified by race. Low BB dose conferred less risk in the presence of A2C-AR polymorphism 
among blacks, but increased risk among whites. This gene polymorphism/BB dose interaction and differential response by race group 
should be examined in a large, prospective study. 
